AI brief of an SEC Form 8-K · Onconetix, Inc. (ONCO)

Onconetix lends up to $5.0 million to Realbotix ahead of pending share exchange

Neutral Impact 3 of 5 financing Written later

Onconetix agreed on September 11, 2026 to lend up to $5.0 million to Realbotix, LLC, the target of its pending all-stock acquisition, with $2.5 million advanced at signing. The loan is non-interest bearing until the acquisition closes or is terminated, and the balance is cancelled at closing, which reduces the cash Onconetix must hold at closing. For shareholders, the filing shows the financing terms but no change to the acquisition's status, which still requires Onconetix shareholder and regulatory approvals.

Key points

  • Loan of up to $5.0 million to Realbotix, with $2.5 million advanced on September 11, 2026; note matures September 11, 2027
  • Note is non-interest bearing until the Share Exchange Agreement closes or terminates; 12% annual interest accrues if terminated
  • At closing, the note is cancelled and the required Net Cash at Closing rises by $500,000 plus the outstanding principal
  • Realbotix Corp. guarantees the note; closing requires at least $12.5 million in Net Cash

The filing

CompanyOnconetix, Inc. (ONCO)
Form8-K, current report
Filed with the SECSep 14, 2026, 10:39 AM ET
Accession number0001213900-26-099524

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.